<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87222">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737151</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14712</org_study_id>
    <secondary_id>NCI-2012-02545</secondary_id>
    <nct_id>NCT01737151</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer</brief_title>
  <official_title>Study of 4-Fraction Split-Course Stereotactic Ablative Radiation Therapy of the Treatment of Patients With Low and Intermediate Risk Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies stereotactic body radiation therapy in treating
      patients with low- and intermediate-risk prostate cancer. Stereotactic body radiation
      therapy may be able to send x-rays directly to the tumor and cause less damage to normal
      tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate, in terms of late toxicity, the safety of stereotactic radiation therapy
      using the proposed fractionation schedule.

      SECONDARY OBJECTIVES:

      I. To evaluate, in terms of acute toxicity, the safety of stereotactic radiation therapy
      using the proposed fractionation schedule.

      II. To determine stereotactic treatment efficacy through biochemical failure (Phoenix
      criteria).

      III. To determine the protocol completion rate.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients undergo standard daily fractions of stereotactic body radiation therapy
      (SBRT) over 7-8.5 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Late toxicity greater than or equal to grade 2 as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Will be tested using a continuity corrected chi-square test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure as defined by the Phoenix definition</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute toxicity greater than or equal to grade 2 as defined by the CTCAE version 4 criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage I Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (standard stereotactic body radiation therapy (SBRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard daily fractions of SBRT over 7-8.5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (four fraction split-course SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 2 fractions of SBRT in weeks 1 and 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Arm I (standard stereotactic body radiation therapy (SBRT)</arm_group_label>
    <other_name>SBRT, stereotactic radiation therapy, stereotactic radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>four fraction split-course SBRT</intervention_name>
    <description>four fraction split-course SBRT</description>
    <arm_group_label>Arm II (four fraction split-course SBRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have low or intermediate risk adenocarcinoma of the prostate as defined
             by:

               -  Low-risk disease - Histopathology score (Gleason sum): =&lt;6, T-stage (per current
                  AJCC staging criteria): T1c-T2a, and PSA: &lt;10

               -  Intermediate-risk disease as either:

                    -  Histopathology score (Gleason sum) =&lt; 6, T-stage (per current American
                       Joint Committee on Cancer [AJCC] staging criteria): T1c-T2a, and
                       prostate-specific antigen (PSA) &gt; 10 but =&lt; 20; or

                    -  Histopathology score (Gleason sum) 7 with =&lt; 50% of any cores positive,
                       T-stage (per current AJCC staging criteria): T1c-T2a, and PSA &lt; 10

          -  Charlson index of comorbidity score =&lt; 4

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with history of inflammatory bowel disease, or who require steroid or
             cytotoxic therapy for collagen vascular disease

          -  Patients with a history of cancer other than skin cancer within 5 years of the
             initiation of protocol treatment

          -  Patients with a history of pelvic irradiation for any reason

          -  Life expectancy &lt; 10 years - Prior treatment with an anti-androgen, luteinizing
             hormone-releasing hormone (LHRH) agonist, or a combination of the two

          -  Prior radiation therapy, brachytherapy, or cryotherapy

          -  Prior surgical procedure involving peri-rectal and peri-prostatic area
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Anscher, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell Anscher, MD</last_name>
    <phone>804-828-7238</phone>
    <email>manscher@mcvh.vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Holdford, RN</last_name>
    <phone>804-828-0296</phone>
    <email>daholdfo@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy N Showalter, MD</last_name>
      <phone>434-243-1462</phone>
      <email>tns3b@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy N Showalter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Anscher, MD</last_name>
      <phone>804-828-7238</phone>
      <email>manscher@mcvh-vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane Holdford, RN</last_name>
      <phone>804-828-0296</phone>
      <email>daholdfo@vcu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell Anscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Skinner, RN</last_name>
      <phone>804-675-5646</phone>
      <email>vicki.skinner@va.gov</email>
    </contact>
    <investigator>
      <last_name>Michael Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
